2 277

Cited 0 times in

A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.

 Gun Min Kim  ;  Hei-Cheul Jeung  ;  Sun Young Rha  ;  Hyo Song Kim  ;  Inkyung Jung  ;  Byung Ho Nam  ;  Kyung Hee Lee  ;  Hyun Cheol Chung 
 EUROPEAN JOURNAL OF CANCER, Vol.48(4) : 518-526, 2012 
Journal Title
Issue Date
Adenocarcinoma/drug therapy* ; Adenocarcinoma/pathology ; Adult ; Aged ; Algorithms ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Capecitabine ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives* ; Disease Progression ; Drug Combinations ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Fluorouracil/analogs & derivatives* ; Humans ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage* ; Organoplatinum Compounds/adverse effects ; Oxonic Acid/administration & dosage* ; Oxonic Acid/adverse effects ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/pathology ; Tegafur/administration & dosage* ; Tegafur/adverse effects ; Treatment Outcome ; Young Adult
S-1 ; Capecitabine ; Gastric cancer ; Oxaliplatin
PURPOSE: S-1 or capecitabine plus oxaliplatin are considered active and tolerable in gastric cancer patients. We conducted a randomized phase II trial in gastric cancer patients to compare the activity and safety of these combinations. METHODS: The patients received S-1 at 80 mg/m2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the S-1/oxaliplatin (SOX) arm, and capecitabine at 2000 mg/m2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the capecitabine/oxaliplatin (CAPOX) arm. Oxaliplatin 130 mg/m2 was administered every 3 weeks in both arms. RESULTS: One hundred twenty-nine patients were randomly assigned to SOX (N=65) or CAPOX (N=64). The median time to progression and the overall survival were 6.2 and 12.4 months with SOX, respectively; and 7.2 and 13.3 months with CAPOX, respectively. The overall response rates were 40% and 44% for SOX and CAPOX, respectively. The most frequent grade 3 or 4 toxicities were thrombocytopenia (15.4%) for SOX and neutropenia (18.8%) for CAPOX. The median time to 10% deteriorations in global health scores was similar in both arms (SOX, 4.3 months, CAPOX, 4.9 months). CONCLUSION: Both the SOX and CAPOX regimens were equally active and well tolerated in advanced gastric cancer patients.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers
Yonsei Authors
Kim, Gun Min(김건민) ORCID logo https://orcid.org/0000-0001-9167-8682
Kim, Hyo Song(김효송) ORCID logo https://orcid.org/0000-0002-0625-9828
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Jung, Inkyung(정인경) ORCID logo https://orcid.org/0000-0003-3780-3213
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.